Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Schwartz

Cardiovascular Disease Derby, CT Medical Doctor

NPI 1588727549 CMS profile 207408

130 Division St Fl 1, Derby, CT 06418

Open in the dashboard

General payments

$6,991

283 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kenneth Schwartz of Derby, CT is reported in the CMS Open Payments database as having received $6,991 across 283 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $736 34
2024 General $1,120 47
2023 General $918 41
2022 General $876 49
2021 General $921 47
2020 General $440 25
2019 General $1,980 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Schwartz
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Kenneth Schwartz were reported at $736. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Kenneth Schwartz Cardiovascular Disease median Middle half National median
2019 $1,980 $450 $127–$1,392 $163
2020 $440 $242 $77–$751 $114
2021 $921 $335 $101–$1,037 $132
2022 $876 $395 $121–$1,211 $149
2023 $918 $443 $136–$1,283 $160
2024 $1,120 $450 $136–$1,323 $164
2025 $736 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $1,422 8 payments
  2. Novartis Pharmaceuticals Corporation $689 42 payments
  3. Pfizer Inc. $687 36 payments
  4. Janssen Pharmaceuticals, Inc $625 34 payments
  5. Merck Sharp & Dohme Corporation $591 26 payments
  6. Amgen Inc. $436 19 payments
  7. E.R. Squibb & Sons, L.L.C. $431 20 payments
  8. Alnylam Pharmaceuticals Inc. $258 11 payments
  9. AstraZeneca Pharmaceuticals LP $237 14 payments
  10. HeartFlow, Inc. $234 9 payments
  11. Other $1,381 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,057 281 payments
  2. Travel and Lodging $934 2 payments
Products named General payments · program years 2019–2025
  1. VERQUVO $790 34 payments
  2. XARELTO $625 34 payments
  3. ELIQUIS Cardiovascular;Metabolic Disease $448 23 payments
  4. Repatha $407 18 payments
  5. VYNDAQEL $347 18 payments
  6. ENTRESTO $321 20 payments
  7. ELIQUIS Cardiovascular $303 15 payments
  8. FFRct $234 9 payments
  9. ONPATTRO $227 10 payments
  10. LEQVIO $215 13 payments
  11. Other $2,621 126 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,439

Median for Cardiology: 2,533

Drug cost

$353,014

Median for Cardiology: $485,213

Branded share of claims

20.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 155 $238,762
Entresto Sacubitril/Valsartan Brand 31 $46,911
Xarelto Rivaroxaban Brand 43 $38,409
Brilinta Ticagrelor Brand 12 $16,033
Metoprolol Succinate Generic 227 $2,760
Rosuvastatin Calcium Generic 83 $1,920
Atorvastatin Calcium Generic 196 $1,759
Ezetimibe Generic 54 $1,020
Losartan Potassium Generic 99 $845
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 22 $772

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$40,174

Medicare's payments for the services billed

Medicare patients

653

Average age 76

Services billed

1,459

332 women, 321 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 44%
Diabetes 38%
Atrial fibrillation 35%
Heart failure 34%
COPD 32%
Chronic kidney disease 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $200
$200 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $102
$102 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $52
  • PFIZER INC. $42
$94 155 —
XARELTO
  • Janssen Pharmaceuticals, Inc $89
$89 43 —
VYNDAQEL
  • PFIZER INC. $74
$74 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

283 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record